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Abstract
Background: Precise genetic modifications are preferred products of CRISPR-Cas9 mediated gene editing in mammalian
cells but require the repair of induced double-strand breaks (DSB) through homology directed repair (HDR). Since HDR
competes with the prevailing non-homologous end joining (NHEJ) pathway and depends on the presence of repair
templates its efficiency is often limited and demands optimized methodology.
Results: For the enhancement of HDR we redirect the DSB repair pathway choice by targeting the Ubiquitin mark for
damaged chromatin at Histone H2A-K15. We used fusions of the Ubiquitin binding domain (UBD) of Rad18 or RNF169 with
BRCA1 to promote HDR initiation and UBD fusions with DNA binding domains to attract donor templates and facilitate HDR
processing. Using a traffic light reporter system in human HEK293 cells we found that the coexpression of both types of UBD
fusion proteins promotes HDR, reduces NHEJ and shifts the HDR/NHEJ balance up to 6-fold. The HDR enhancing effect of
UBD fusion proteins was confirmed at multiple endogenous loci.
Conclusions: Our findings provide a novel efficient approach to promote precise gene editing in human cells.
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Background
The RNA guided Cas9 nuclease is a versatile tool for
genome editing in mammalian cells by creation of tar-
geted double-strand breaks (DSBs) [1]. Gene editing at
Cas9 induced DSBs is achieved by two alternative DSB
repair pathways, either by non-homologous end joining
(NHEJ) that leads to randomly sized small deletions or
insertions (Indels), or by homology-directed repair
(HDR) enabling precise sequence modifications that are
copied from a repair template molecule. Since HDR is
restricted to the S and G2 phases of the cell cycle [2]
and requires the presence of a repair template it occurs
notably less frequently than NHEJ, presenting a barrier
for all applications that rely on precise sequence
modifications, such as modelling of disease mutations or
the correction of mutations in somatic gene therapy. To
reinforce precise gene editing, tools or interventions are
required that bias DSB repair pathway choice in favor of
HDR and that promote HDR processing by the targeted
delivery of DNA repair templates to DSBs. In particular
the availability of repair templates may present a rate
limiting factor for HDR. Previous approaches for the tar-
geted delivery of repair templates used Cas9 fusion pro-
teins with domains binding to a functional group that is
incorporated into synthetic oligonucleotides or PCR
fragments as donor templates and that are delivered into
cells as combined Cas9-sgRNA-donor complexes [3–5].
However, it is presently unknown whether the link of
the repair template molecule to Cas9 nuclease is the
most effective way for codelivery, since the template is
required during later steps of DSB repair. Previous ap-
proaches to promote DSB repair pathway choice in favor
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of HDR include the enrichment of cells in the S/G2
phase [6, 7], restriction of Cas9 activity to the S/G2
phase [8, 9], inhibition of NHEJ key molecules [10, 11]
and the use of Cas9 fusion proteins with the HDR ef-
fector CtIP [12]. Nevertheless, these interventions do not
directly target the protein complexes determining the re-
pair pathway choice at the DSB ends, that presumably
represent an effective target to promote HDR. The path-
way choice for DSB repair is influenced by the interplay
between the regulatory proteins BRCA1 and 53BP1,
leading either to the resection or protection of DSB ends
and the subsequent engagement of the HDR or NHEJ
pathway (Fig. 1a) [13–15]. The 53BP1 protein has been
identified as the key regulator for the initiation of DSB
repair by NHEJ and represents a prime target for inter-
ventions aiming for suppression of NHEJ. 53BP1 is re-
cruited to DSBs by recognition of the key Ubiquitin
mark for damaged chromatin [16], set by the E3 Ubiqui-
tin ligase RNF168 at Lysine 15 of histone H2A (H2A-
K15Ub) in nucleosomes flanking the break sites (Fig. 1a)
[17–20]. To suppress the recruitment of 53BP1 to DSBs,
earlier studies used a dominant negative 53BP1 subdo-
main [21] or modified Rad18 [22] for masking of the
H2A-K15Ub site or developed the inhibitor i53, a mutant
Ubiquitin that blocks the H2A-K15Ub recognition do-
main of 53BP1 [23]. The inhibition of 53BP1 accumula-
tion alleviates a barrier in the accessibility of HDR
initiating factors at DSB sites and leads to a 2–3-fold
stimulation of HDR. Furthermore, it has been found that
H2A-K15Ub together with the acidic patch on the nu-
cleosome surface is also recognized by the Ubiquitin
binding domains (UBD) of Rad18, RNF168 and RNF169
[24, 25]. Since the UBD of Rad18 and RNF169 bind
H2A-K15Ub with substantial higher affinity than RNF168
or 53BP1, the overexpression of Rad18 or RNF169 leads
to the displacement of 53BP1 from DNA repair foci [26,
27]. In contrast to 53BP1, Rad18 and RNF169 also
recognize the Ubiquitin mark at H2A-K13 but exhibit
substantially lower affinity as compared to the H2A-
K15Ub site [25].
We reasoned that the UBD of Rad18 (Rad18UBD) and
RNF169 (RNF169UBD) may provide powerful tools for
the stimulation of HDR since they target high affinity
H2A-K15Ub binding sites at the hub of DSB repair.
Hence, the fusion of Rad18UBD and RNF169UBD with
proteins stimulating HDR could fulfill the dual purpose
of loading DSB sites with effectors of choice and of
NHEJ suppression through displacement of 53BP1. As
effector domains either proteins that directly stimulate
HDR can be used or fusions with DNA binding domains
that link the DSB with a repair template that includes
the respective binding site. Here, we present this novel
approach for HDR stimulation by using a traffic-light
DSB reporter (TLR) system for the quantitative
detection of HDR and NHEJ events in human HEK and
induced pluripotent stem cells. We found that the fusion
of Rad18UBD or RNF169UBD with BRCA1 increases the
ratio of HDR/NHEJ 3.6–4.1-fold. A comparable increase
of HDR can be obtained by using UBD fusion proteins
with the Tet repressor (TetR) or Gal4 DNA binding do-
mains to enrich repair template molecules that include
TetR or Gal4 binding sequences at DSB sites. Combined
expression of a BRCA1-UBD together with a TetR- or
Gal4-UBD is most effective, shifting in HEK293 cells the
HDR/NHEJ ratio at the reporter and endogenous loci up
to 6-fold.
Results
DSB repair assays in traffic light reporter cells
To quantitatively determine CRISPR/Cas9-induced DSB
repair by HDR or NHEJ, we integrated a ‘traffic light’ re-
porter (TLR) construct into the Adeno-Associated Virus
Integration Site 1 (AAVS1) locus of human HEK293
cells and human induced pluripotent stem cells (hIPSC).
In HEK cells the reporter construct TLR-6 includes a
CAG promoter for expression of a nonfunctional coding
region for Yellow fluorescent (Venus) protein in reading
frame + 1, disrupted by the replacement of codons 95–
97 with a 23 bp gRNA target sequence from the mouse
Rosa26 locus (sgRosa), followed by a P2A peptide and
the coding region for a red fluorescent (TagRFP) protein
in reading frame + 2 (TLR-6) (Fig. 1b). CRISPR/Cas9-in-
duced DSBs in the TLR-6 target region that are repaired
via NHEJ and cause the deletion of 1 basepair (or of 1 +
3, 1 + 6 bp, etc.) shift the translation to the frame of
P2A-TagRFP and are detectable in reporter cells by RFP
expression. If an intact Venus coding region is provided
as repair template and DSB repair occurs via the HDR
pathway the reporter cells are detected by the expression
of Venus (Fig. 1b). To generate a HEK293 reporter line,
cells were transfected with an AAVS1 targeting vector
carrying the TLR-6 insert along with Cas9 and an
AAVS1-specific sgRNA expression plasmid. We selected
a homozygously targeted HEK293 clone (HEKTLR6) for
DSB repair assays. For activation of the reporter we
transfected HEKTLR6 reporter cells with a vector for ex-
pression of Cas9, sgRosa and a blue fluorescent protein
(BFP) together with a circular donor plasmid (pTLR-
donor) for repair of the defective Venus reporter gene.
The cells were analyzed 72 h after transfection by flow
cytometry, gated on the BFP+ transfected population
(Fig. 1c). Within the BFP+ population the frequency of
Venus+ and of RFP+ cells was determined. Since
HEKTLR6 cells are homozygous for the reporter con-
struct a small population of double positive cells appears
as well, undergoing HDR repair on one reporter allele
and a mutagenic NHEJ event on the other reporter al-
lele. The total number of Venus and RFP positive cells
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was calculated by addition of the values of single and
double positive cells. As shown in Fig. 1d, using
HEKTLR6 cells we observed 6.2% of Venus+ and 25.1% of
RFP+ cells indicating HDR or RFP activating NHEJ re-
pair events of the reporter in the ratio of 0.25, as com-
pared to 24.9% RFP+ and background levels of 1.1%
Venus+ cells in a control lacking pTLR-donor. The
unexpected background of Venus+ cells in the absence
of the repair template was explained by a specific 14 bp
deletion event that occurs in a small fraction of cells and
reconstitutes the Venus reading frame and the critical
arginine codon 96 (Figure S1). Transfection samples in-
cluding pTLR-donor were subtracted for background
levels determined in the same experiment. In hiPSC we
Fig. 1 DSB repair assays in TLR reporter cells. a Diagram of DSB repair pathway choice and ubiquitination of histone H2A at DNA double-strand breaks (DSB).
Upon DSB induction, regulatory proteins bind to ubiquitin at positions K13 and K15 via ubiquitin-binding domains (UBDs). The 53BP1 and BRCA1 regulatory
proteins play an important role in DSB repair pathway choice. DSB repair is executed by repair proteins and leads either to non-homologous end ligation
(NHEJ) or homology-directed repair (HDR). If the NHEJ pathway is chosen, the DNA ends religate, frequently associated with nucleotide deletions or insertions.
The HDR pathway enables precise sequence modifications if a DNA repair template is available. b The ‘traffic light’ reporter (TLR) system indicates the ratio of
DSB repair by NHEJ or HDR. Upon induction of DSBs in the target region using CRISPR-Cas9, RFP is expressed when repair by NHEJ results in deletions that shift
translation into the RFP reading frame. Venus expression reports for HDR when an intact Venus coding region is cotransfected. c Gating scheme for BFP
positive cells in transfected HEK and hiPS reporter cells. Single cells were gated by using a forward scatter (FSC-H vs. FSC-A) plot. Transfected cells were gated
based on expression of BFP from transfected plasmids compared to non-transfected control. d TLR assay in HEK or hiPS reporter cells. At least 10,000 cells were
analyzed per sample for the Venus or RFP positive population. Double positive cells in the HEKTLR6 clone are gated using an extra window
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used a previously described TLR construct [11] that is simi-
lar to TLR-6 except that codons 117–152 of Venus were re-
placed by the sgRosa target sequence and the P2A-TagRFP
is expressed in the + 3 reading frame upon the deletion of 2
basepairs (or of 2 + 3, 2 + 6 bp, etc.). In hiPSC we targeted
one AAVS1 allele using a vector carrying the TLR insert
and inserted a vector for the constitutive expression of Cas9
into the second AAVS1 allele. Upon transfection of hiPSC
reporter cells with sgRosa and pTLR-donor plasmids we ob-
served 2.17% of RFP+ and 9% of Venus+ cells (Fig. 1d), indi-
cating that HDR repair in hiPS cells is more proficient than
mutagenic NHEJ as compared to HEK cells. No RFP+ or
Venus+ cells were observed in untransfected controls.
DSB repair modification by Rad18UBD and RNF169UBD
fusion proteins in traffic light reporter cells
For the fusion of the UBD binding domains from RAD18
or RNF169 we used two types of proteins: either the en-
dogenous BRCA1 protein acting as HDR enhancer or a
DNA binding domain from bacterial Tet repressor (TetR)
or yeast Gal4 for recognition of sequence motifs that must
be included in the targeting vector. Upon DSB induction
and H2A-K15 ubiquitination these fusion proteins should
cover the DSB ends, compete with 53BP1, and support
HDR by increasing the local concentrations of BRCA1
and the HDR repair template (Fig. 2a). For the expression
of BRCA1, TetR or Gal4 fusions with the UBD of Rad18
(Rad18UBD) or RNF169 (RNF169UBD) we used plasmids
carrying a CAG promoter and a BFP reporter gene (Fig.
2b). To enable the accumulation of repair templates at
DSB sites by TetR- or Gal4-UBD proteins we cloned Tet
operator (tetO) or UAS recognition sequences into the
pTLR-donor vector adjacent to the TLR homology region.
For DSB repair assays HEKTLR6 cells were cotransfected
with plasmids for expression of Cas9, sgRosa, pTLR donor
and plasmids for the expression of UBD fusion proteins.
hiPS reporter cells exhibiting constitutive Cas9 expression
were cotransfected with plasmids for sgRosa, UBD fusion
proteins and pTLR-donor vector. Three days after transfec-
tion the frequency of Venus+ and RFP+ cells was deter-
mined by FACS. The ratio of Venus+/RFP+ cells is used as
indicator for DSB repair choice by HDR or mutagenic
NHEJ leading to RFP expression as determined by FACS
analysis. We first expressed the Rad18UBD or RNF169UBD
domain alone to assess their effect in HEKTLR6 reporter
cells. As shown in Fig. 3 the expression of Rad18UBD
slightly diminished the Venus+ cell population but signifi-
cantly reduced the number of RFP+ cells by 60%. A similar,
but weaker effect was observed for RNF169UBD that re-
duced the frequency of RFP+ cells by 30% (Fig. 3). Thus,
the expression of Rad18UBD and RNF169UBD domains alone
inhibits NHEJ but does not enhance HDR. The reduction
of NHEJ repair is in agreement with previous findings that
Rad18UBD and RNF169UBD domains compete with 53BP1
for H2A-K15Ub binding sites [26, 27]. We confirmed in our
experimental settings that the Rad18UBD domain colocalizes
with phosphorylated H2AX at DSB repair foci (Figure S2).
Next, we assessed the effect of UBD fusion proteins on
HDR and NHEJ events in HEKTLR6 reporter cells by
FACS analysis (Fig. 4). First we determined the effect of
Fig. 2 UBD expression vectors and transfection of TLR reporter cells. a UBD fusion proteins can compete with 53BP1 for binding at H2A-K15 and
suppress NHEJ. BRCA1-UBD fusion proteins can direct this HDR factor to DSBs, while fusion with Tet repressor (TetR) or Gal4 attract the repair
template molecule that include TetO or UAS binding sites, supporting HDR processing. b Plasmids constructed for expression of the Ubiquitin
binding domain (UBD) of Rad18 of RNF169 in fusion with the coding region of BRCA1, Tet repressor or Gal4, driven by the CAG promoter.
Plasmids include an EF1-BFP reporter gene to facilitate the FACS-based analysis
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BRCA1 alone and of BRCA1 in fusion with UBDs of
Rad18 or RNF169 in comparison to i53 as NHEJ inhibi-
tor. The expression of i53 increased the Venus/RFP ratio
from 0.32 to 1.69 (Fig. 4 sample 3) as compared to the
control (sample 2). The expression of BRCA1 (sample 4)
lead only to a smaller reduction of RFP+ cells and an in-
crease of Venus+ cells (Venus/RFP ratio: 0.64). In con-
trast, the expression of BRCA1-Rad18UBD or BRCA1-
RNF169UBD fusion proteins (samples 5 and 6) leads to a
more than 3-fold increase of Venus+ cells and to the re-
duction of RFP+ cells by more than half, shifting the
Venus/RFP ratio to 2.56 and 2.8, respectively. The ex-
pression of TetR-Rad18UBD or TetR-RNF169UBD fusion
proteins (samples 7 and 8) lead to a more than 2-fold re-
duction of RFP+ cells and more than 2-fold increase of
Venus+ cells, shifting the Venus/RFP ratio to 1.99 and
1.85, respectively. The combination of i53 with BRCA1-
Rad18UBD or BRCA1-RNF169UBD (samples 9 and 10) did
not lead to a further increase of the Venus/RFP ratio as
compared to the use of the fusion proteins alone. In
contrast, the effect of TetR-Rad18UBD and TetR-
RNF169UBD (samples 11 and 12) was enhanced in the
presence of i53, shifting the Venus/RFP ratio to 2.94 and
3.79, respectively. Next, we explored whether BRCA1-
and TetR-Rad18UBD or -RNF169UBD fusion proteins can
be combined to further increase HDR frequency. As
compared to the use of single fusion proteins, we ob-
served in both combinations (samples 13 and 14) an in-
crease of the Venus/RFP ratio to values of 4.06 or 3.61,
respectively. Finally, we compared the effect of UBD fu-
sions with the full length Rad18 or RNF169 proteins
(samples 15 and 16). Expression of Rad18 leads to a
Venus/RFP ratio of 0.36, comparable to the control,
whereas RNF169 expression moderately increased the
Venus/RFP ratio to a value of 1.08.
In addition, we tested the DNA binding domain of the
yeast transcription factor Gal4 as alternative to TetR and
included ten copies of its 17 bp UAS recognition se-
quence into pTLR-donor (pTLR-donor-UAS). The ex-
pression of Gal4-Rad18UBD or Gal4-RNF169UBD alone
increased the Venus/RFP ratio in HEKTLR6 cells from
0.34 to values of 1.37 or 2.0 and to 3.14 or 3.29 together
with BRCA1 fusion proteins (Figure S3), similar to the
effect of TetR-UBD fusion proteins.
Fig. 3 Expression of isolated UBDs in HEKTLR6 cells. HEKTLR6 cells were cotransfected in triplicates using sgRNA, Cas9, pTLR-donor and unfused
UBDs of Rad18 and RNF169, driven by the CAG promoter. Transfected cells were gated based on expression of BFP and the percentage of Venus
(HDR) (green bars) or RFP (NHEJ) (red bars) positive cells was determined by FACS analysis. The expression of these UBDs decreases NHEJ as
detectable by RFP expression but do not enhance HDR. Gene editing efficiency is expressed as percentage of Venus (HDR) (green bars) or RFP
(NHEJ) (red bars) positive cells normalized to values of sample 1 (sgRosa/Cas9). Data are shown as mean values ± SD from two independent
experiments, each with three replicates per samples, normalized to the values of the first (control) sample. Significance of values in comparison to
the control with sgRosa/Cas9 and TLR-donor was determined by two-way ANOVA and Dunnett’s multiple comparison tests with **P < 0.01,
***P < 0.001. Raw data are shown in the Supplementary data file
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For the sequence-based analysis of gene editing prod-
ucts we amplified the reporter target region using cells
from one of the HEKTLR6 FACS assay (Fig. 4) and per-
formed amplicon sequencing. The NGS based analysis of
repair products showed essentially the same effects as ob-
served in the FACS-based analysis. The transfection of
Cas9, sgRosa and pTLR-donor-tetO resulted in a HDR/
NHEJ ratio of 0.42 that increased up to 2.22 or 2.52 by the
coexpression of BRCA1- and TetR-Rad18UBD or BRCA1-
and TetR-RNF169UBD fusion proteins, respectively (Figure
S4). As expected for sequence analysis the fractions of
NHEJ products were higher and the fraction of HDR
products lowered, since FACS analysis detects only Indel
products that lead to RFP expression in reading frame + 2.
To this end, we analyzed the distribution of reading
frames and found that NHEJ repair products in frame + 2
were prevailing in all samples (Figure S5). Therefore, RFP
expression measured by FACS is able to detect the major-
ity of NHEJ repair products and the coexpression of DSB
repair modifiers did not bias the distribution of reading
frames among the Indel products.
We further assessed the activity of Rad18UBD and
RNF169UBD fusion proteins in hiPS TLR reporter cells by
FACS. In hIPC cells the expression of i53, BRCA1 or
BRCA1-Rad18UBD proteins did not lead to a significant in-
crease of Venus+ cells, in contrast to TetR-UBD fusions.
BRCA1 and TetR fusion proteins in combination lead to a
4–6-fold increase of the Venus/RFP ratio (Figure S6, sam-
ples 12, 13) as compared to the control (sample 2), similar
to the observation in HEKTLR6 cells (Fig. 4). The expres-
sion of full length Rad18 or RNF169 proteins had no sig-
nificant effect on the number of Venus+ cells.
These results show that the UBD of Rad18 and
RNF169 are effective tools for the manipulation of DSB
repair pathway choice at the reporter locus. While the
UBD alone reduces NHEJ, its fusion with BRCA1 or
with a DNA binding domain associating with the repair
template increases DSB repair by HDR. Each of the
Fig. 4 Fluorescence-based DSB repair assay using Rad18UBD and RNF169UBD fusion proteins in HEKTLR6 reporter cells. Fusion constructs for BRCA1 or TetR with
Rad18UBD or RNF169 UBD were cotransfected with the TLR HDR repair template (TLR-donor-tetO), sgRNA and Cas9 into HEKTLR6 cells. The frequency of Venus+
cells (green bars) and RFP+ cells (red bars) within the population of BFP+ cells was measured by FACS analysis 72 h after transfection and used to calculate the
ratio of Venus/RFP positive cells. The X-axis shows the transfected samples and the selection of cotransfected plasmids below. Samples 1 and 2 are controls
showing the basic frequency of Venus+ and RFP+ cells upon transfection with Cas9 and sgRNA or in combination with TLR-donor-tetO as repair template. Data
from four independent experiments, each with three replicates per sample, are represented as mean values ± SD. Statistical significance of samples 3–16 in
comparison to the control sample 2 was determined by two-way ANOVA and Dunnett’s multiple comparison tests with **P<0.01, ***P < 0.001 (HDR) and
##P< 0.01, ###P< 0.001 (NHEJ). Raw data are shown in the Supplementary data file
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fusion proteins alone exhibits an effect on the HDR/
NHEJ ratio that is stronger than the i53 NHEJ inhibitor.
Highest levels are reached by the combination of two
Rad18UBD or RNF169UBD fusion proteins. Under these
conditions, HDR events in HEKTLR6 cells are increased
> 2-fold and NHEJ events reduced > 2-fold, shifting the
HDR/NHEJ ratio by a factor of up to 6-fold (Figure S4
sample 2 vs 14).
Targeting of endogenous genes in HEK cells
We further confirmed the effect of UBD fusion proteins
on DSB repair by targeting of five endogenous loci in
the HEK cell genome. The LMNA (Lamin A), GABPA
(GA binding protein transcription factor alpha subunit),
CREB1 (cyclic AMP-responsive element-binding protein
1), and the AAVS1 loci were targeted for the insertion of
a 78 bp sequence encoding a triple FLAG Tag. Each gene
was targeted using a repair template vector with tetO el-
ements and homology regions (0.5–0.9 kb) flanking the
Tag insertion (Fig. 5a). Upon the transfection of HEK
cells with donor vector together with Cas9, sgRNA and
UBD fusion proteins the target regions were amplified
and gene editing events were analysed by amplicon se-
quencing (Fig. 5a). This analysis revealed for LMNA,
GABPA and AAVS1 but not CREB1 a significant in-
crease of HDR upon coexpression of BRCA1- and TetR-
Rad18UBD fusion proteins as compared to the control
transfected only with Cas9, sgRNA and donor template
(Fig. 5b-d). At CREB1, GABPA and AAVS1 but not
LMNA, the coexpression of Rad18UBD fusion proteins
also lead to a significant decrease in NHEJ events. At the
GABPA and AAVS1 loci the decrease of NHEJ was com-
parable to CREB1, but the increase in HDR was consid-
erably stronger upon coexpression of Rad18UBD fusion
proteins, notably 11.2-fold for GABPA and 7.1-fold for
AAVS1 (Fig. 5c, e). This shifted the HDR/NHEJ balance
of DSB repair at the GABPA and AAVS1 loci by a factor
of 29 and 15, respectively. Likewise the coexpression of
BRCA1- and TetR-RNF169UBD fusion proteins shifted
the HDR/NHEJ ratio at all indicated loci by a factor of
at least 1.8 (Fig. 5b-e). Their combined expression lead
to a 1.5, 10, 2.1 and 10.5-fold increase in HDR for the
LMNA, GABPA, CREB1, and AAVS1 loci respectively,
whereas NHEJ was suppressed at least 2.3 fold at the
three latter loci (Fig. 5b-e).
For targeting of the LMNB1 (Lamin B1) gene we used
a donor vector with tetO elements and a larger insert for
the N-terminal fusion of GFP with LMNB1 (Fig. 6a).
HEK cells were transfected either with Cas9, sgRNA and
the LMNB1 donor alone or together with UBD fusion
proteins and after 10 days the HDR frequency was deter-
mined by FACS as the number of GFP+ cells. As com-
pared to the control (Fig. 6b, sample 2) the coexpression
of a single Rad18UBD or RNF169UBD fusion protein
increased the number of GFP+ cells by up to 32% (sam-
ple 5–8). The coexpression of TetR fusions (sample 7
and 8) or both types of Rad18UBD (sample 9) or
RNF169UBD fusion proteins (sample 10) significantly in-
creased the number of GFP+ cells by up to 49%. Taken
together, these results demonstrate that Rad18UBD and
RNF169UBD fusion proteins also support HDR at en-
dogenous target genes in HEK cells. The strongest ef-
fects were observed by the combined expression of UBD
fusion proteins with BRCA1 and TetR together with re-
pair donor vectors that include tetO binding sites.
Discussion
We show that the H2A-K15 Ubiquitin mark at CRISPR-
Cas9 induced DSBs can be utilized for shifting DSB re-
pair towards HDR, supporting precise gene editing. This
is achieved by using the Ubiquitin binding domain of
Rad18 or RNF169 in fusion with BRCA1 as HDR enhan-
cer or the TetR or Gal4 DNA binding domain for con-
necting the repair vector to the DSB site. Since HDR
requires the appropriate pathway choice and the pres-
ence of the repair template we achieved best results by
the combined expression of both types of fusion pro-
teins. These combinations strongly increased the ratio of
HDR/NHEJ repair at multiple genomic targets.
Previous studies for HDR stimulation did not actively
target DNA damage ubiquitination but either used Cas9
fusion proteins [4, 5, 12], targeted enzymes at earlier or
later stages of DSB repair [10, 11, 28], confined Cas9 activ-
ity to the S/G2 cell cycle phases [6–9] or suppressed NHEJ
by interfering with 53BP1 binding to H2A-K15ub using
i53 [23], a dominant-negative 53BP1 subdomain [21] or a
modified Rad18 protein [22]. In contrast, our UBD fusion
protein approach manipulates DSB repair pathway choice
not only by targeting of the 53BP1 binding site but also
enables the active positioning of HDR enhancers and
donor vectors at DSB sites. The former but not the latter
feature can be also reached by small molecule (SCR7) [11]
or peptide (i53) [23] inhibitors of NHEJ that are conveni-
ently used in tissue culture. However, our direct compari-
son of UBD fusion proteins to the peptide inhibitor of
53BP1 showed that each fusion protein exhibits a stronger
effect than i53. Highest levels (up to 6-fold in HEKTLR6
cells) were reached by the combination of two Rad18UBD
or RNF169UBD fusion proteins.
The initial configuration of this approach as presented
here is using the full length BRCA1 protein as HDR en-
hancer and a second UBD fusion protein with a TetR or
Gal4 DNA binding domain for the attraction of the
donor vector. To avoid the expression of two modifier
proteins in future further studies will be required to de-
fine whether its design can be simplified by use of
BRCA1 subdomains and whether the HDR enhancing
domain can be combined with a DNA binding domain
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Fig. 5 Knockin of a triple FLAG Tag into endogenous genes in HEK cells. a Schematic drawing of the targeting strategy at the endogenous LMNA, GABPA,
CREB1, and AAVS1 loci. HEK cells were transfected with expression vectors for Cas9, sgRNA and a donor vector with tetO elements for introduction of a triple
FLAG sequence into the first or last exon of the GABPA (exon 10), CREB1 (exon 9) or LMNA (exon 1) gene and into the AAVS1 site of the PPP1RC12C (first
intron) gene, respectively. Three days after transfection, genomic DNA was isolated and the target region was amplified by a two-step PCR reaction using the
indicated primers (arrows, green: Illumina adapter). The secondary PCR products were sequenced by amplicon sequencing. b, c, d, e. DSB repair events were
quantified by deep sequencing reads for each target gene. The fraction of reads showing HDR (green bars) or Indel events (red bars) is shown on the Y-axis in
relation to the total number of reads showing wildtype or gene editing events and was used to calculate the ratio of HDR/NHEJ DSB repair. The table shows
the selection of cotransfected plasmids of each sample for the expression of Cas9, sgRNA and BRCA1- and TetR- with Rad18UBD or RNF169UBD fusion proteins.
Data are presented as mean values ± SD from two independent experiments. *P<0.05, **P < 0.01 (HDR) and #P< 0.05, ##P < 0.01 (NHEJ); t-test. Raw data are
shown in the Supplementary data file
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into a single fusion protein. Furthermore, it will be inter-
esting to test whether BRCA1 can be replaced by one of
its interaction partners, such as BRCA2 or Palb2. In
addition, the DNA binding domains derived from TetR
and Gal4 may be replaced by other domains for the rec-
ognition of double-stranded or single-stranded DNA
donor templates, as shown for the link between Biotin
or Benzylguanine conjugated oligodeoxynucleotides and
Cas9 fusions with the SNAP-Tag or Avidin [4, 5]. Such
modifications could result into a streamlined system for
delivery into cells or tissues as plasmid, mRNA or as re-
combinant HDR enhancer protein together with Cas9/
gRNA complexes by microinjection, electroporation or
as nanoparticles.
In this study we employed a traffic light reporter sys-
tem for the assessment of DSB repair activity by HDR
and NHEJ in HEK and hiPS cells that we used earlier to
validate DNA Ligase IV as target for NHEJ suppression.
Fig. 6 Knockin of GFP into the LMNB1 gene. a Schema of the human LMNB1 gene exon 1, Cas9 target site and the donor vector for the insertion of the GFP
coding region downstream of the LMNB1 start codon, flanked by 5′- and 3′- homology arms. Upon homologous recombination (HDR) a GFP/LMNB1 fusion
protein is produced. b HEK cells were transfected either with the tetO modified LMNB1 targeting vector (LMNB1-donor-tetO) alone or together with an
expression vector for LMNB1-sgRNA and Cas9 (sgLMNB1/Cas9) or with expression vectors for BRCA1, BRCA1-Rad18UBD, BRCA-RNF169UBD, TetR-Rad18UBD or
TetR-RNF169UBD as shown in the table. The HDR frequency was determined as the number of GFP positive cells using FACS analysis 10 days after transfection
and its relative increase in comparison to the control sample 2 is given as HDR score. Statistical significance of samples 3–10 in comparison to the control
sample 2 was determined by ordinary one-way ANOVA and Dunnett’s multiple comparison tests with *P < 0.05, **P < 0.01, ***P<0.001. Data from three
independent experiments, each with three replicates per sample, are presented as mean values ± S.D. Raw data are shown in the Supplementary data file
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Since the TLR-6 reporter enables to detect only a frac-
tion of NHEJ events by RFP expression upon the recon-
stitution of the + 2 reading frame and it was recently
shown that the spectrum of DSB repair products is
biased depending on the target sequence [29, 30], we
compared the analysis of HEKTLR6 reporter cells by
FACS and amplicon sequencing. These results showed
that for the TLR-6 reporter DSB repair products in the
reading frame + 2 were dominating and its RFP expres-
sion reflects the majority of mutagenic NHEJ events.
Nevertheless, due to the lack of reporter activity in the
other reading frames the FACS based analysis leads to
an overestimation of the ratio of DSB repair by HDR or
NHEJ as compared to amplicon sequencing. Based on
the sequencing results the HDR/NHEJ balance at the re-
porter locus is shifted up to 6-fold in the presence of
BRCA1 and TetR fusion proteins. A similar strong shift
was observed at the GABPA, CREB1 and AAVS1 loci
whereas at LMNA the suppression of NHEJ was not
pronounced, pointing to a locus variability that requires
further investigation. Furthermore, it is possible that the
positive effect of UBD fusion proteins will be greatest if
highly specific sgRNAs are used together with an off-
target improved Cas9 nuclease, since the presence of
additional DSBs at off-target sites may divert UBD fu-
sion proteins from acting at the on-target site. To this
end it will be interesting to compare the effect of using
sgRNAs together with wildtype Cas9 in comparison to
the off-target improved eCas9 [31], Cas9-Hifi [32] and
other variants. In the present work we did not discrimin-
ate between DSB repair choice in the G1 and S/G2 cell
cycle phases. We anticipate that HDR enhancement oc-
curs primarily in the S/G2 phases in which the HDR
pathway is fully available. It has been shown that HDR
can be at least partially reactivated in G1 by the com-
bined suppression of 53BP1 and the expression of a deg-
radation resistant Palb2 mutant together with a
phosphomimetic CtIP mutant [33]. Therefore it will be
interesting to determine the effect of the H2A-K15Ub ap-
proach specifically on DSB repair in the G1 phase and
whether its current configuration or further modifica-
tions will enable HDR mediated DSB repair in the G1
phase or in resting cells. Based on previous studies [24,
27] we assume that the expression of Rad18UBD or
RNF169UBD fusion proteins leads to the partial displace-
ment of 53BP1 from its ubiquitin binding sites at DSBs.
In the present work we did not study competition with
53BP1 but confirmed the presence of Rad18UBD protein
in γH2AX foci.
In the current format of using plasmid based expres-
sion vectors we expect that the H2A-K15Ub approach
can readily support applications of precise gene editing
in human cell lines such as the modelling or correction
of disease causing mutations by cotransfection with
Cas9/sgRNA vectors. In the format of recombinant pro-
teins its applications may be extended in future to pri-
mary human cells such as hematopoietic stem cells,
muscle satellite or other primary cells to assess its utility
for the precise correction of mutations required for som-
atic gene therapy. Since DSB repair mechanism are con-
served in evolution and DSB associated 53BP1 foci have
been identified in various mammals, Xenopus and zebra-
fish [34–37], we envision that the targeting of 53BP1
binding sites can also be applied for HDR enhancement
in other vertebrate species.
Conclusions
The present study describes a new strategy for the en-
hancement of HDR in human cells. DSB repair pathway
choice can be redirected by fusion proteins of Ubiquitin
binding domains that localize at DSB sites, shifting the
HDR/NHEJ balance several fold. These findings provide
an efficient approach to promote precise gene editing in




pAAVS1-TLR6 was constructed by generation of a 1552
bp fusion PCR product from a 329 bp PCR fragment
(using primers TLRvenus-1 and TLR6–1) and a 1247 bp
PCR fragment (using primers TLR6–2 and TagRFP-3),
using pAAVS1-TLR donor (Addgene ID 64215) [11] as
template, into the backbone of plasmid pCAG-
venusTarget+1P2A + 3TagRFP (opened with PacI and
MluI), resulting into pCAG-TLR6. pCAG-TLR6 was used
for isolation of a 3.2 kb AscI-AsiSI fragment that was li-
gated into pAAVS1-TLR (opened with AsiSI and AscI),
resulting into pAAVS1-TLR6, serving as AAVS1 targeting
vector with the TLR6 reporter insert. pU6Rosa-CAG-Cas9
for expression of Rosa26 sgRNA and Streptococcus pyo-
genes (Sp) Cas9 was constructed by ligation of the DNA
oligonucleotides sgRosa-A and sgRosa-B into the BbsI
sites downstream of a human U6 promoter into plasmid
pU6(BbsI). The U6-sgRosa cassette was recovered as AscI
fragment and inserted into pCAG-Cas9-bpA-EF1-BFP,
upstream of the CAG promoter driving SpCas9 expres-
sion, followed by a BFP coding region under control of
the human EF1α promoter. Plasmid pTLR-donor was gen-
erated by whole plasmid PCR amplification using 5′-phos-
phorylated primers TLRtv-1 and TLRtv-2 and pTLR-
repair (Addgene ID 64322) [11] as template, followed by
DpnI digestion of the template and religation of the PCR
fragment. The modification of pTLR-repair removes the
Start codon of the Venus coding region, eliminating back-
ground fluorescence upon transient transfection. For con-
struction of pTLR-donor-tetO, pTLR-donor was opened
with SalI and ligated with a 448 bp SalI fragment from
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plasmid pTREtightbi, a derivative of pTREtight (Clontech)
that contains seven Tet operator elements. For construc-
tion of plasmid pTLR-donor-UAS, pTLR-donor was
opened with SalI and ligated with two tandem copies of a
151 bp PCR fragment amplified with primers UAS-for/
UAS-rev, each containing 5 UAS elements, using plasmid
pUAS-luc2 (Addgene ID 24343) as template. Plasmid
pCAG-Rad18UBD was constructed by generation of a
225 bp PCR fragment, including the UBD domain of hu-
man Rad18 between codon 191–240, amplified from plas-
mid myc-hRad18 (Addgene ID 68827) as template using
primers Rad18-for and -rev. The PCR product was incu-
bated with DpnI to remove the plasmid template, digested
with PacI and MluI and ligated into the backbone of plas-
mid pCAG-Rad51-bpA-EF1-BFP opened with Pac and
MluI. Plasmid pU6Rosa-CAG-Rad18 for expression of
Rad18 was constructed by amplification of a 1536 bp PCR
product, including the full length human Rad18 coding re-
gion, using primers Rad18-for2 and -rev2 and Addgene
plasmid 68,827 as template. The PCR product was incu-
bated with DpnI, digested with PacI and MluI and ligated
into the PacI-MluI sites of plasmid pU6Rosa-CAG-Rad51-
bpA-EF1BFP, replacing the Rad51 coding region. Plasmid
pCAG-RNF169UBD for expression of the RNF169UBD
was constructed by amplification of a 219 bp PCR frag-
ment, including the UBD domain of human RNF169 be-
tween codon 662–709, using plasmid pcDNA5-FRT/TO-
Flag-RNF169 (Addgene ID 74243) as template with
primers RNF169-for2 and -rev. The PCR product was in-
cubated with DpnI, digested with PacI and MluI and li-
gated into the backbone of plasmid pCAG-Rad51-bpA-
EF1-BFP opened with Pac and MluI. Plasmid pCAG-
RNF169 for expression of the full length human RNF169
was constructed by ligation of a 2167 bp PCR product
amplified with primers RNF169-for and –rev (using a syn-
thetic gene as template) into the backbone of plasmid
pCAG-Rad51-bpA-EF1-BFP opened with Pac and MluI.
Plasmid pCAG-BRCA1 for expression of BRCA1 was con-
structed by amplification of 5640 bp PCR fragment, in-
cluding the full length human BRCA1 coding region,
using plasmid pDEST-FRT/T0-GFP-BRCA1 (Addgene ID
71116) as template and primers BRCA1-for and -rev. The
PCR product was incubated with DpnI, digested with PacI
and MluI and ligated into the backbone of plasmid
pCAG-Rad51-bpA-EF1-BFP opened with Pac and MluI.
Plasmid pCAG-i53 was constructed by amplification of a
273 bp PCR fragment, including the i53 coding region,
using plasmid pcDNA3-Flag-UbvG08 (Addgene ID
74939) as template and primers i51-for and -rev. The PCR
product was incubated with DpnI, digested with PacI and
MluI and ligated into the backbone of plasmid pCAG-
Rad51-bpA-EF1-BFP opened with Pac and MluI. Plasmids
pCAG-BRCA1-, pCAG-TetR-, and pCAG-Gal4-Rad18UBD
for expression of Rad18UBD fusion proteins were constructed
by amplification of specific PCR products that were digested
with PacI and PvuI and ligated into the PacI site of pCAG-
Rad18UBD. BRCA1 was amplified as 5681 bp PCR product
using primers BRCA1-for and -rev2 and pCAG-BRCA1 as
template, The TetR coding region was amplified as 1445 bp
PCR fragment using primers TetRsc4-for and –rev and
plasmid pU6MS2Rosa-CAG-MS2ditetRsc as template.
pU6MS2Rosa-CAG-MS2ditetRsc was generated by cloning
of a 739 bp PCR fragment amplified with primers scTetR-
for2 and rev2 from pU6MS2Rosa-CAG-MS2ditetR into the
PmlI site of pU6MS2Rosa-CAG-MS2ditetR to duplicate the
TetR coding region, separated by 5 copies of a (GGGGS)
linker, to generate a single chain Tet repressor coding region
as described. We used a single chain TetR that combines two
TetR monomers separated by a linker sequence [38] to enable
the binding of TetR fusion proteins as a single protein. The
Gal4 DNA binding domain was amplified as 561 bp PCR
fragment from pActPL-Gal4DBD (Addgene ID 15304) using
primers Gal4-for and –rev. The same PCR products were li-
gated into the PacI site of pCAG-RNF169UBD to generate
the plasmids pCAG-BRCA1-RNF169UBD, pCAG-TetR-
RNF169UBD and pCAG-Gal4-RNF169UBD for the expres-
sion of RNF169UBD fusion proteins. The AAVS1 targeting
vector for Cas9 expression pAAVSI-NEOwt-CAG-Cas9v3a-
bpA was generated by isolation of a 4.7 kb PacI-XhoI frag-
ment isolated from pCAG-Cas9v3a-bpA followed by ligation
into the AflII and SalI site of pAAVS1-NEOwt CAG-tetR-
donor U6 acceptor, a derivative of Addgene plasmid 60,431.
PX458_GABPA_2 and PX458_CREB1_1 were a gift from
Eric Mendenhall & Richard M. Myers (Addgene plasmid #
64255 and 64,939). For cloning of pU6LMNB1-CAG-Cas9
the DNA oligonucleotides sgLMNB1-A and sgLMNB1-B
(target sequence: GGGGTCGCAGTCGCCATGGC) were
annealed and ligated into the BbsI sites downstream of a hu-
man U6 promoter into plasmid pU6(BbsI) chimaeric RNA.
The U6-sgRNA fragment was then PCR amplified and cloned
into the AscI site of CAG-Cas9-EF1-BFP. The same approach
was used to clone sgRNA against LMNA (target sequence:
TGGGACGGGGTCTCCATGGC) and AAVS1 (target se-
quence: GGGGCCACTAGGGACAGGAT) using oligo-
nucleotide pairs sgLMNA-A/−B and sgAAVS1-A/−B. To
construct the targeting vector pTetO-CREB1-3xFLAG a 1.5
kb fragment containing the CREB1 homology arms (HA)
flanking 3X FLAG Tag insert was synthesized (Thermo Fi-
scher Scientific). This fragment was then cloned via SgfI/ SpeI
sites into the plasmid backbone of pTLR-donor-tetO. The
same strategy was used to derive pTetO-GABPA-3xFLAG (2
kb HA), pTetO-AAVS1-3xFLAG (1.6 kb HA) and pTetO-
LMNA-3xFLAG (1.1 kb HA) that were synthesized and
cloned into the SgfI/SpeI sites of pTLR-donor-tetO. To clone
pTetO7-LMNB1-GFP, the 448 bp SalI fragment was isolated
from pTLR-donor-tetO and ligated upon end filling into the
SnaBI site of AICSDP-10:LMNB1-mEGFP (Addgene
#87422). All coding regions and functional elements of the
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constructed plasmids were confirmed by Sanger sequencing.
The plasmids will be distributed via the Addgene repository
(www.addgene.org).
Generation of reporter cell lines
The human IPS cell lines BCRT and JWT (a kind gift of
Harald Stachelscheid, BIH, Berlin) were used to generate
TLR-Cas9 transgenic cell lines. These lines were grown
in feeder-free conditions in Essential 8 (E8) or E8 Flex
complete media (Thermofischer Scientific, #A1517001)
on Vitronectin (Life Technologies, #A14700) coating in
a 6-well cell culture plate. Plasmid DNA (pbs-U6-
sgAAVS1-T2 (Addgene ID 41818), pAAVS1-TLR [11]
and pAAVS1-NEOwt-CAG-Cas9v3a-bpA vector were
diluted at a concentration of 0.5 μg/μl in deionized
water. The AAVS1-TLR and -Cas9 Knockin vectors har-
bor a Puromycin and Neomycin (G418) antibiotic resist-
ance marker respectively for the selection of targeted
clones. Passaging was performed using PBS-EDTA dis-
sociation buffer in fresh media containing Y27632 select-
ive ROCK Inhibitor (Tebu-Bio, #21910–2301-2). The
cells were transfected using Lipofectamine 3000 trans-
fection reagent (Life Technologies, #L3000001) using
1 μg plasmid each for sgRNA, Cas9 and TLR vectors fol-
lowing manufacturer’s protocol. Puromycin (Sigma-Al-
drich #P8833-25MG) (0.5 μg/ml) selection was started
48 h after transfection and continued until single col-
onies were formed. Puromycin resistant single clones
were picked and then selected by using G418 (Thermo-
Fisher #11811064) at the concentration of 100 μg/ml for
10 days. After the antibiotic selection, 24 colonies were
expanded for genotyping. Genomic DNA was isolated
using Wizard genomic DNA purification kit (Promega
#A1125). Genotyping PCRs were performed for knock-
in of TLR construct (puro 5′) and Cas9 (Neo 5′) as well
as AAVS1 WT locus specific as a control. The PCR re-
action for TLR Knockin was performed using primers
ST_puro_gt_fw and ST_puro_gt_rv, Phusion HF DNA
polymerase (NEB # M0530 L) and 200 ng genomic DNA
using following conditions; 98 °C for 3 min, 35 cycles of
98 °C 30 s, 58 °C 30 s and 72 °C for 90 s. Cas9 KI was
confirmed by Neo 5′ KI PCR using primers ST_neo_gt_
fw and ST_neo_gt_rv using conditions at 98 °C for 5
min, followed by 35 cycles of 98 °C 30 s, 61 °C 30s, 72 °C
for 90 s. AAVS1 WT PCR was performed using primers
hAAVS1-For and hAAVS1-Rev by amplifying at 98 °C
for 5 min, followed by 40 cycles of 98 °C 30 s, 60 °C 30 s,
72 °C for 45 s. After confirmation of TLR and Cas9 in-
sertion by genotyping, selected clones were tested for ac-
tivity of the TLR allele by FACS-based assay and one
clone was chosen for further assays. The expression of
Cas9 and of pluripotency markers in TLR/Cas9 reporter
cells was confirmed by immunofluorescence staining.
HEK293 cells were maintained in Dulbecco’s Modified
Eagle’s medium with Glutamax (Gibco) supplied with
10% fetal bovine serum (Gibco). The HEKTLR6 line was
generated by using pAAVS1-TLR6, the same AAVS1
targeting vector as described above for the TLR con-
struct with the difference that the TLR6 insert can be
used for both plasmid and ssODN-based repair. The
transfections for generation of the HEKTLR6 line were
performed using sgRNA for AAVS1 and Cas9 plasmids
(750 ng each) using Xtreme-gene transfection reagent
(Roche #6366244001). Antibiotic selection was per-
formed using 0.4 μg/ml Puromycin. Single clones were
generated and genotyped in the same way as described
above for the iPS TLR/Cas9 lines. All cell lines were
confirmed for the absence of mycoplasma using the PCR
assay of Uphoff and Drexler [39].
Transfection of cells
TLR/Cas9 transgenic iPS cells were passaged one day
prior to transfection using PBS-EDTA dissociation buf-
fer. Plasmid vectors sgRNA-Rosa3, TLR donor template
and one or a combination of Rad18UBD or RNF169UBD
fusion vectors (750 ng each) were transfected using Lipo-
fectamine 3000 (Thermo Fisher Scientific) according to
manufacturer’s protocol. HEKTLR6 cells were seeded in
24-well plates (50,000 cells per well) one day before
transfection. Cells were transfected with pU6Rosa-CAG-
Cas9, pTLR-donor-tetO or pTLR-donor-UAS template
and one or two plasmids for the expression of Rad18UBD
or RNF169UBD fusion proteins (375 ng each) using
Xtreme gene transfection reagent (Merck) according to
manufacturer’s protocol. All samples were transfected in
triplicate wells. For the targeting of endogenous genes in
HEK293, cells were seeded in 48-well plates (50,000 cells
per well) one day before transfection. The transfection
of HEK293 cells were performed using sgRNA for the
targeted locus, Cas9, targeting vector and/or the fusion
proteins (360 ng each plasmid per well) using Xtreme-
gene transfection reagent.
Analysis of HDR and NHEJ by flow cytometry
FACS analysis for TLR reporter assays was performed
upon 72 h after transfection. For preparation of cells for
FACS analysis the medium was aspirated from wells and
each well was washed with PBS. Accutase (Thermo
Fisher Scientific, #A1110501) was used to detach iPS
cells while Trypsin was used for the HEK cells. The cells
were collected after adding appropriate media by centri-
fugation at 300 g for 4 min and finally resuspended in
500 μl PBS. The cells were kept on ice and FACS ana-
lysis was performed immediately. Single cells were gated
for BFP positive populations and the frequency of Venus
(HDR) and RFP (NHEJ) positive cells was determined
using a BD LSR Fortessa flow cytometer (BD
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Biosciences). The analysis of the entire population (with-
out BFP gating) leads to the same proportion of Venus
and RFP positive cells but lower absolute numbers. The
results from triplicate wells of each sample were used to
calculate the mean value and standard deviation. For the
FACS analysis of LMNB1-GFP Knockin in HEK cells,
the medium was aspirated from wells and each well was
washed with PBS. The cells were then harvested using
Trypsin and collected down after adding appropriate
media by centrifugation at 300 g for 4 min and finally re-
suspended in 500 μl PBS. The cells were kept on ice and
FACS analysis was performed immediately. For LMNB1-
GFP assay single cells were gated for the frequency of
GFP positive cells reporting for HDR using BD LSR For-
tessa flow cytometer (BD Biosciences). Flow cytometry
settings were controlled by using untransfected cells or
cells transfected with a BFP or Venus expression vector
as shown in Figure S7.
Amplicon sequencing
For the TLR locus the frequency of NHEJ and HDR was
determined by Illumina amplicon sequencing via Gene-
wiz (Amplicon EZ; GENEWIZ Germany GmbH). For
this purpose, DNA was isolated from pooled triplicates
of the same experiment used for FACS (Fig. 4). An outer
PCR reaction (591 bp) was performed using primers lo-
cated outside the homology arms, while a second PCR
reaction was performed using primers amplifying a
shorter PCR product of 245 bp. For the first PCR reac-
tion primers CAG2 and Venus-rev were used alongwith
Optitaq DNA polymerase (Roboklon, # E2600–02) and
200 ng DNA per reaction using these conditions; initial
denaturation at 95 °C for 1 min, followed by 35 cycles of
95 °C 20 s, 61 °C 35 s and 72 °C for 40 s and final exten-
sion at 72 °C for 5 min. For the second PCR amplifica-
tion, Venus-for-Ilumina and Venus-rev-illumina Optitaq
DNA polymerase and 20 ng of purified 1st PCR product
following these conditions; initial denaturation at 95 °C
for 2 min, followed by 35 cycles of 95 °C 20s, 61 °C 25 s,
72 °C for 40 s and final extension 72 °C for 5 min.
For the LMNA, GABPA, CREB1 and AAVS1 loci, the fre-
quency of NHEJ and HDR was determined by Illumina
amplicon sequencing via Genewiz (Amplicon EZ; GENE
WIZ Germany GmbH). DNA was isolated from each well
and a first PCR was performed using primers with at least
one primer binding site locating outside the homology arm
(Table S1). For the CREBP1 and GABPA gene, the PCR re-
action was performed using hCREBP1 5HDR-F + hCREBP1-
3HA intern-R and hGABPA 5HA intern-F + hGABPA 3-
HR-R primers, LongAmp DNA polymerase (Neb #M0323S)
and 200 ng DNA per reaction using these conditions; initial
denaturation at 94 °C for 30 s, followed by 35 cycles of 94 °C
15 s, 59 °C 40 s and 65 °C for 1min 30 s. Final extension was
done at 65 °C for 10min. For the AAVS1 and LMNA locus,
the PCR reaction was performed using HR-AAVS1-F +
AAVS1-R and LMNA-outer-F + LMNA-outer-R primers,
LongAmp DNA polymerase (Neb #M0323S) and 200 ng
DNA per reaction using these conditions; initial denaturation
at 94 °C for 30 s, followed by 35 cycles of 94 °C 15 s, 61 °C 40
s and 65 °C for 1min 30 s/2min (AAVS1/LMNA). Final ex-
tension was done at 65 °C for 10min. The second PCR amp-
lification was performed using following primers (Primer
LMNA 3′ inner fw_illumina, Primer LMNA 3′ inner rev_
illumina, hGABPA_ intFw_illumina, hGABPA_ intRev_illu-
mina, hCREB1_IntFw_Illumina, hCREBP1_intRev_Illumina,
AAVS1 inner fw_illumina, and AAVS1 inner rev_illumina),
Q5 DNA polymerase (Neb #M0491S) and 50 ng of gelex-
tracted 1st PCR product with these conditions; initial de-
naturation at 98 °C for 30 s, followed by 35 cycles of 98 °C 10
s, 62 °C 30 s, 72 °C for 15 s and final extension at 72 °C for 2
min. The PCR products were purified on column using the
GeneJET PCR Purification Kit (Thermo Scientific, #K0702).
2 μg of each purified PCR reaction was submitted for deep
sequencing. The analysis of deep sequencing data was per-
formed using Crispresso [40] and Crispresso2 (http://cris-
presso.pinellolab.partners.org/) online bioinformatics tools
designed for analysis of Crispr-based gene editing data. Add-
itionally, a custom Amplicon-sequencing analysis pipeline (li-
censed from Bioinformatics. Expert UG, Berlin, Germany)
was used for data analysis which needs the rawdata fastq-
files for the paired reads as well as the reference sequence
provided as fasta-file. The main functionalities of that pipe-
line were implemented in R statistics (version: 3.6.0). The
alignment algorithm was performed using the R function
“pairwiseAlignment()” from the R package Biostrings (ver-
sion: 2.52.0). In a first step, the paired reads were aggregated
and cleaned to reduce potential technical sequencing errors.
This was done for each pair of reads as following: First, the
R2-read was converted to its reverse complement sequence,
the quality score was reversed. Second, the R1- and R2-read
were aligned locally to identify the overlap between the read
pairs. The local alignment was performed with very high
penalty values for gap opening and gap extension to avoid an
alignment with gaps, which might shift the bases during ag-
gregation. Third, R1 and the reverse complement R2-
sequence (rcR2) were stitched together at the aligned se-
quence. If bases differ between R1 and rcR2, the base was
chosen, which had the highest quality score on that position.
Missing bases at the end were filled with “N”. Fourth, the 15
bases from the 5′ and 3′ ends of the reference sequence
were aligned locally to the aggregated sequence to identify
the sequence boundaries. In this step, two mismatches or
two Insertions/Deletions were allowed. Afterwards, all bases
in front or after the alignment were chopped. So, a final ag-
gregated sequence was created for each read, which starts
and ends with the boundary bases of the reference sequence.
In the second part of the pipeline, all aggregated reads were
then aligned globally to the reference sequence (alignment
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reward/penalty scores: match = 1, mismatch = 0, gapOpen =
− 2, gapExtension = 0). The alignment scores were chosen to
favor long gaps over small gaps and mismatches. Finally, all
unique aggregated sequences were sorted and counted.
Statistics
For all experiments, data are shown as mean ± standard
deviation. Statistical significance was determined as indi-
cated in each results part. A P value of less than 0.05
was considered statistically significant. Statistical analysis
was performed using GraphPad Prism 8 (GraphPad Soft-
ware Inc., San Diego, USA).
Synthetic Oligodeoxynucleotides
Synthetic oligonucleotides used in this study were pur-
chased from Eurofins Genomics (Ebersberg, Germany)
and are shown in Table S1.
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Additional file 1: Figure S1. Analysis of Venus positive cells in HEKTLR6
cells upon transfection with Cas9 and Rosa26 specific sgRNA. Positive cells
(0.48%) were isolated by FACS sorting and the target region was
amplified from genomic DNA, subcloned and sequenced. Two analysed
clones (Seq clone A, B) showed a deletion of 14 bp that removes a part
of the Rosa26 target sequence and restores the Venus reading frame and
the critical Arginine codon 96 (R96). The adjacent codons 95 and 97 are
also replaced (T, W) but seemingly do not disrupt Venus fluorescence.
(PDF, 195 kb) (EPS 561 kb)
Additional file 2: Figure S2. Intracellular localization of Rad18UBD
protein in HEK cells. HEK293 cells were transfected with an expression
vector for FLAG tagged Cas9 (pX330, Addgene 42,230) (A) or FLAG
tagged Rad18UBD (B) using XtremeGene transfection reagent. After 48 h
cells were treated for 10 min with H2O2 (500 μM) and fixed after 1 h in
4% paraformaldehyde. Fixed cells were stained in PBS, 0.2% Triton X-100,
3% BSA with antibodies against phospho-H2AX (mouse mAb, clone
JBW301, Millipore #05–636, 1:500) and FLAG Tag (rabbit mAb, Cell Signal-
ing Technology # 14793, 1:800) for 1 h. After washing slides were incu-
bated for 1 h with secondary goat antibodies against mouse IgG (Alexa
Fluor 594, Life Technologies #A-11032, 1:1000) and rabbit IgG (Alexa Fluor
488, Life Technologies A11034, 1:1000), washed and incubated for 10 min
in Hoechst 33342 stain (Life Technologies H3670, 1:2000). After washing
images were acquired using a Keyence BZ9000 microscope. In (B) the
FLAG Tag signals are colocalized with γH2AX foci. (PDF, 986 kb)
Additional file 3: Figure S3. DSB repair modification by Gal4-Rad18UBD
and -RNF169UBD fusion proteins in HEKTLR6 reporter cells. Fusion constructs
for Gal4 or BRCA1 with Rad18UBD or RNF169 UBD were cotransfected with
the matching TLR HDR repair template (TLR-donor-UAS), sgRNA and Cas9
into HEKTLR6 cells. The frequency of Venus and RFP positive cells was
measured by FACS analysis 72 h after transfection. The HDR frequency is
reported by Venus (green bars) while the fraction of NHEJ events in
reading frame + 2 is reported by RFP expression (red bars). The bars
represent mean values ± standard deviation, Y-axis represents the fre-
quency of Venus or RFP positive cells in percent while the X-axis shows
samples transfected in combinations, as shown in the table below. Sam-
ples 1 and 2 are controls showing the basic frequency of RFP+ only and
of Venus+ cells in addition when TLR-donor-UAS is provided as repair
template. As compared to BRCA1 alone (sample 3) the expression of
BRCA1-Rad18UBD or RNF169UBD fusions strongly increased the Venus/RFP
ratio to values of 2.94 and 3.0 (samples 4 and 5). The expression of Gal4-
Rad18UBD or Gal4-RNF169UBD increased the Venus/RFP ratio by a factor of
4 or 5.9, from 0.34 (sample 2) to values of 1.37 or 2.0 (samples 6 and 7).
The combined expression of Gal4-UBD with BRCA1-UBD fusions further
increased the Venus/RFP ratio to a value of 3.14 in fusion with Rad18UBD
and to 3.29 in fusion with RNF169UBD. This increase however was mostly
if not entirely attributed to the effect of BRCA1-UBD fusion proteins alone
that lead to HDR/NHEJ ratios of 2.94 and 3.0 (samples 4 and 5). Data from
three independent experiments, each with three replicates per sample,
are presented as mean values ± S.D. Significance of samples in compari-
son to the control sample 2 with sgRosa/Cas9 and TLR-donor-UAS was
determined by two-way ANOVA and Dunnett’s multiple comparison tests
with ***P < 0.001 (HDR) and ###P < 0.001 (NHEJ). (PDF, 271 kb). Raw data
are shown in the Supplementary data file. (EPS 313 kb)
Additional file 4: Figure S4. Sequence-based DSB repair assay using
Rad18UBD and RNF169UBD fusion proteins in HEKTLR6 reporter cells.
Transfected reporter cells from one of the assays analysed by FACS (Fig.
4; experiment 1 in the supplement data file) were used for PCR
amplification of the reporter target region from genomic DNA (A),
isolated from pooled cells of the triplicate samples used for FACS analysis
72 h after transfection. (B) PCR products were sequenced by amplicon
sequencing and the fraction of reads showing HDR (green bars) or Indel
events (red bars) is shown in relation to the total number of reads with
gene editing events on the Y-axis and was used to calculate the ratio of
HDR/NHEJ DSB repair. The X-axis shows the transfected samples and the
selection of cotransfected plasmids below. Samples 1 and 2 are controls
showing the basic frequency of Venus+ and RFP+ cells upon transfection
with Cas9 and sgRNA or in combination with TLR-donor-tetO as repair
template. The fraction of sequence reads representing the 14 bp deletion
causing Venus background expression (Figure S1) is given as ‘percent
background’. Raw data are shown in the Supplementary data file. (EPS
1295 kb)
Additional file 5: Figure S5. Distribution of reading frames within the
mutagenic NHEJ repair products in HEKTLR6 reporter cells. Using CRISPResso
analysis of the amplicon sequencing data shown in Figure S4 we
calculated for each sample the distribution of the reading frames + 1
(Venus expression frame), + 2 and + 3 among the repair products
showing + 1 insertions or deletions from − 1 to − 12 nucleotides. RFP
expression becomes activated in the TLR-6 construct in the reading frame
+ 2 by the deletion of 1, 4, 7 or 10 nucleotides. Of note, the frequency of
reading frame + 2 products is lowest in sample 1 in the absence of pTLR-
donor. Raw data are shown in the Supplementary data file.
Additional file 6: Figure S6. DSB repair modification by Rad18UBD and
RNF169UBD fusion proteins in hiPS reporter cells. Fusion constructs for
BRCA1 or TetR with Rad18UBD or RNF169 UBD were cotransfected with the
TLR HDR repair template (TLR-donor-tetO), sgRNA and Cas9 and analysed
for Venus and RFP positive cells using FACS analysis 72 h after
transfection. The HDR frequency is reported by Venus (green bars) while
the fraction of NHEJ events in reading frame + 3 is reported by RFP
expression (red bars). The bars represent mean values ± standard
deviation, Y-axis represents the frequency of Venus or RFP positive cells
in percent while the X-axis shows samples transfected in combinations,
as shown in the table below. Controls show the basic frequency of RFP+
cells upon transfection of Cas9 plus sgRNA, and of Venus+ and RFP+ cells
in the presence of the repair template TLR-donor-tetO. Expression of i53,
BRCA1 or BRCA1-UBD fusion proteins showed levels of Venus+ cells that
were statistically not significantly different as compared to sample 2, ex-
cept for BRCA1-RNF169UBD (samples 5–8) and the TetR-UBD fusions (sam-
ple 7 and 8). The coexpression of i53 with a single Rad18UBD or RNF169
UBD fusion (samples 9–12) significantly enhanced the Venus/RFP ratio by
a factor of 7–16.6. The combined expression of the two fusion proteins
BRCA1-Rad18UBD and TetR-Rad18UBD (sample 13) or BRCA1-RNF169UBD
and TetR-RNF169UBD (sample 14) led to 4–6-fold increase of the Venus/
RFP ratio . The expression of full length Rad18 or RNF169 proteins (sam-
ple 15 and 16) did not show significant difference to the control sample.
Data are shown as mean values ± SD from two independent experiments
into BCRT or JWT iPS cells, each with three replicates per samples, nor-
malized to the values of sample 2 as control. Statistical significance of
values in comparison to the control sample 2 with sgRosa/Cas9 and TLR-
donor-tetO was determined by two-way ANOVA and Dunnett’s multiple
comparison tests with *P < 0.05, **P < 0.01, ***P < 0.001 (HDR) and ##P <
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0.01, ###P < 0.001 (NHEJ). Raw data are shown in the Supplementary data
file. (EPS 449 kb)
Additional file 7: Figure S7. Flow cytometry controls for DSB repair
assay in TLR reporter cells. FACS gating scheme for BFP and Venus
positive cells in HEKTLR6 reporter cells. Cells were untransfected (A) or
transfected either with pU6Rosa-CAG-Cas9 with pTLR donor (B) or with a
Venus (C) or BFP (D) expression plasmid. Single cells were gated by using
a forward scatter plot. Transfected cells were gated based on expression
of BFP, Venus or RFP compared to the non-transfected control. The frac-
tion of positive cells in the defined windows is indicated. Raw data are
shown in the Supplementary data file. (EPS 1761 kb)
Additional file 8: Table S1. List of primers and oligonucleotides.
Additional file 9: Supplementary data file. Raw data points as used
for Figs. 3, 4, 5, 6, and Fig. S3, S4, S5, S6, S7.
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